Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739596 · ClinicalTrials.gov registry record · Phase 4
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 332
- Enrollment target
NCT00739596: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.
NCT00739596 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 332 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00739596, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 332 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
Primary Outcome
To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.
Interventions
- DRUG Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks
- DRUG Amlodipine: 8 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
What the finished NCT00739596 record still lists
NCT00739596 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks is the first listed.
NCT00739596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00739596 about?
NCT00739596 is a clinical study titled "Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans". The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
What is the current status of trial NCT00739596?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 332 participants. The study started on 2008-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00739596?
The interventions under investigation include: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks (DRUG), Amlodipine: 8 weeks (DRUG).
Who is sponsoring clinical trial NCT00739596?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00739596's enrollment target sits among peer trials
332 253rd of 2000 higher than 1,748 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia